Parkinson Disease

Neurology·MeSH: Parkinson Disease

Prevalence

150.0 / 100K

Incidence

15.0 / 100K/yr

28 drugs in development·17 companies·40 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
crexont	Impax Laboratories, LLC (IPXL)

Phase 3(1)

Drug	Company
Rivastigmine Transdermal System	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(13)

Drug	Company
Active drug	ACADIA PHARMACEUTICALS INC (ACAD)
biib122	Denali Therapeutics Inc. (DNLI)
BIIB122	BIOGEN INC. (BIIB)
gt-02287	Gain Therapeutics, Inc. (GANX)
high dose gt-02287	Gain Therapeutics, Inc. (GANX)
ins-gsh	GH Research PLC (GHRS)
lenrispodun	Intra-Cellular Therapies, Inc. (ITCI)
lenrispodun (ITI-214)	Intra-Cellular Therapies, Inc. (ITCI)
low dose gt-02287	Gain Therapeutics, Inc. (GANX)
NEU-411	Crinetics Pharmaceuticals, Inc. (CRNX)
Pimavanserin	ACADIA PHARMACEUTICALS INC (ACAD)
Suvecaltamide	Jazz Pharmaceuticals plc (JAZZ)
Temsirolimus	ELI LILLY & Co (LLY)

Phase 1(4)

Unknown(3)

Drug	Company
15-0 h20	National Research Corporation Common Stock (Delaware) (NRC)
15-0 h20	GH Research PLC (GHRS)
15-0 H20	Valneva SE (VALN)

N/A(1)

Drug	Company
Tavapadon	AbbVie Inc. (ABBV)

Phase 1/Phase 2(2)

Drug	Company
gene therapy	Calidi Biotherapeutics Inc. (CLDI)
ly3884961	Prevail Therapeutics Inc. (PRVL)

Phase 4(3)

Drug	Company
crexont er	Impax Laboratories, LLC (IPXL)
Pimavanserin 34 milligrams [Nuplazid]	ACADIA PHARMACEUTICALS INC (ACAD)
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]	ACADIA PHARMACEUTICALS INC (ACAD)

BioSniper tracks 28 drugs in development for Parkinson Disease across 17 companies.

There are 40 clinical trials targeting Parkinson Disease tracked by BioSniper.

The estimated prevalence of Parkinson Disease is approximately 150.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.